| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Winton Matthew | COO | C/O INOZYME PHARMA, INC., 321 SUMMER STREET SUITE 400, BOSTON | /s/ Sanjay Subramanian, as attorney-in-fact for Matthew Winton | 27 Jun 2025 | 0001971400 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | INZY | Common Stock | Award | $10,623 | +14,355 | +194% | $0.7400 | 21,743 | 25 Jun 2025 | Direct | F1 |
| Id | Content |
|---|---|
| F1 | Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of April 1, 2025 through June 25, 2025. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on April 1, 2025, the first trading day of the purchase period. |